ixekizumab
Sign in to saveAlso known as LY2439821, LY-2439821
Ixekizumab, sold under the brand name Taltz, is an injectable medication for the treatment of autoimmune diseases. Chemically, it is a form of a humanized monoclonal antibody. The substance acts by binding interleukin 17A and neutralizing it, reducing inflammation.
In the Vinony graph
Within Vinony's link graph, ixekizumab is referenced by 409 other articles, and connects out to antibody, monoclonal antibody and biological half-life.
It is catalogued under topics including Chemicals that do not have a ChemSpider ID assigned, Disease-modifying antirheumatic drugs and Drugboxes which contain changes to verified fields.
Its subject is documented across 12 Wikipedia language editions.
Key facts
- Drug.Verifiedfields
- changed
- Drug.verifiedrevid
- 458270595
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- zu
- Drug.target
- Interleukin 17A (IL-17A)
- Drug.pronounce
- ix-ee-KIZ-ue-mab
- Drug.tradename
- Taltz
- Drug.MedlinePlus
- a616025
- Drug.DailyMedID
- Ixekizumab
- Drug.pregnancy_AU
- C
- Drug.routes_of_administration
- Subcutaneous injection
- Drug.ATC_prefix
- L04
- Drug.ATC_suffix
- AC13
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
via Wikipedia infobox
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Antibody
- First approval
- 2016
- Admin. routes
- parenteral
- Indications
- psoriasis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis
via ChEMBL · EBI
Research
1,469 papers- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.The New England journal of medicine · 2016
- Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.Drugs of today (Barcelona, Spain : 1998) · 2023
- Ixekizumab for treating ankylosing spondylitis.Immunotherapy · 2019
- Ixekizumab for the treatment of psoriasis: up-to-date.Expert opinion on biological therapy · 2020
- Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.Lancet (London, England) · 2017
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 2 more facts
- subject has role
- monoclonal antibody
- defined daily dose
- 2.9
Sources (6)
via Wikidata · CC0
~6 min read
Encyclopedic overview
11 sectionsContents
- Medical uses
- Contraindications
- Adverse effects
- Overdose
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemistry
- History
- References
Ixekizumab, sold under the brand name Taltz, is an injectable medication for the treatment of autoimmune diseases. Chemically, it is a form of a humanized monoclonal antibody. The substance acts by binding interleukin 17A and neutralizing it, reducing inflammation.
The most common side effects include upper respiratory infections, injection site reactions and fungal (tinea) infections.
Excerpted from Wikipedia’s “ixekizumab” article, available under the CC BY-SA 4.0 licence.